Home-based subcutaneous immunoglobulin for chronic inflammatory demyelinating polyneuropathy patients: A Swiss cost-minimization analysis
PURPOSE: To compare the cost of two patient management strategies with similar efficacies for chronic inflammatory demyelinating polyneuropathy (CIDP) patients in the chronic phase: hospital-based IV immunoglobulin G (IVIg) and home-based subcutaneous immunoglobulin G (SCIg) associated with an inter...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7688145/ https://www.ncbi.nlm.nih.gov/pubmed/33237959 http://dx.doi.org/10.1371/journal.pone.0242630 |
_version_ | 1783613651917209600 |
---|---|
author | Perraudin, Clémence Bourdin, Aline Vicino, Alex Kuntzer, Thierry Bugnon, Olivier Berger, Jérôme |
author_facet | Perraudin, Clémence Bourdin, Aline Vicino, Alex Kuntzer, Thierry Bugnon, Olivier Berger, Jérôme |
author_sort | Perraudin, Clémence |
collection | PubMed |
description | PURPOSE: To compare the cost of two patient management strategies with similar efficacies for chronic inflammatory demyelinating polyneuropathy (CIDP) patients in the chronic phase: hospital-based IV immunoglobulin G (IVIg) and home-based subcutaneous immunoglobulin G (SCIg) associated with an interprofessional drug therapy management programme (initial training and follow-up). METHODS: A 48-week model-based cost-minimization analysis from a societal perspective was performed. Resources included immunoglobulin (IVIg: 1 g/kg/3 weeks; SCIg: 0.4 g/kg/week initially and 0.2 g/kg/week in the maintenance phase), hospital charges, time of professionals, infusion material, transport and losses of productivity for patients. Costs were expressed in Swiss francs (CHF) (1 CHF = 0.93€ = US$1.10, www.xe.com, 2020/10/28). RESULTS: The total costs of IVIg were higher than those of SCIg for health insurance and other payers: 114,747 CHF versus 86,558 CHF and 8,762 CHF versus 2,401 CHF, respectively. The results were sensitive to the immunoglobulin doses, as this was the main cost driver. The SCIg daily cost in the initial phase was higher for health insurance than hospital-based IVIg was, but the additional costs were compensated during the maintenance phase (from week 28). The professional costs associated with the switch were not fully covered by the insurance and were borne by the pharmacist and the nurse. CONCLUSIONS: SCIg for CIDP patients reinforced by an interprofessional drug therapy management programme may be a cost-effective and sustainable alternative to IVIg in the Swiss system context. From an economic perspective, this therapy alternative should be more widely supported by healthcare systems and proposed to eligible patients by professionals. |
format | Online Article Text |
id | pubmed-7688145 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-76881452020-12-05 Home-based subcutaneous immunoglobulin for chronic inflammatory demyelinating polyneuropathy patients: A Swiss cost-minimization analysis Perraudin, Clémence Bourdin, Aline Vicino, Alex Kuntzer, Thierry Bugnon, Olivier Berger, Jérôme PLoS One Research Article PURPOSE: To compare the cost of two patient management strategies with similar efficacies for chronic inflammatory demyelinating polyneuropathy (CIDP) patients in the chronic phase: hospital-based IV immunoglobulin G (IVIg) and home-based subcutaneous immunoglobulin G (SCIg) associated with an interprofessional drug therapy management programme (initial training and follow-up). METHODS: A 48-week model-based cost-minimization analysis from a societal perspective was performed. Resources included immunoglobulin (IVIg: 1 g/kg/3 weeks; SCIg: 0.4 g/kg/week initially and 0.2 g/kg/week in the maintenance phase), hospital charges, time of professionals, infusion material, transport and losses of productivity for patients. Costs were expressed in Swiss francs (CHF) (1 CHF = 0.93€ = US$1.10, www.xe.com, 2020/10/28). RESULTS: The total costs of IVIg were higher than those of SCIg for health insurance and other payers: 114,747 CHF versus 86,558 CHF and 8,762 CHF versus 2,401 CHF, respectively. The results were sensitive to the immunoglobulin doses, as this was the main cost driver. The SCIg daily cost in the initial phase was higher for health insurance than hospital-based IVIg was, but the additional costs were compensated during the maintenance phase (from week 28). The professional costs associated with the switch were not fully covered by the insurance and were borne by the pharmacist and the nurse. CONCLUSIONS: SCIg for CIDP patients reinforced by an interprofessional drug therapy management programme may be a cost-effective and sustainable alternative to IVIg in the Swiss system context. From an economic perspective, this therapy alternative should be more widely supported by healthcare systems and proposed to eligible patients by professionals. Public Library of Science 2020-11-25 /pmc/articles/PMC7688145/ /pubmed/33237959 http://dx.doi.org/10.1371/journal.pone.0242630 Text en © 2020 Perraudin et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Perraudin, Clémence Bourdin, Aline Vicino, Alex Kuntzer, Thierry Bugnon, Olivier Berger, Jérôme Home-based subcutaneous immunoglobulin for chronic inflammatory demyelinating polyneuropathy patients: A Swiss cost-minimization analysis |
title | Home-based subcutaneous immunoglobulin for chronic inflammatory demyelinating polyneuropathy patients: A Swiss cost-minimization analysis |
title_full | Home-based subcutaneous immunoglobulin for chronic inflammatory demyelinating polyneuropathy patients: A Swiss cost-minimization analysis |
title_fullStr | Home-based subcutaneous immunoglobulin for chronic inflammatory demyelinating polyneuropathy patients: A Swiss cost-minimization analysis |
title_full_unstemmed | Home-based subcutaneous immunoglobulin for chronic inflammatory demyelinating polyneuropathy patients: A Swiss cost-minimization analysis |
title_short | Home-based subcutaneous immunoglobulin for chronic inflammatory demyelinating polyneuropathy patients: A Swiss cost-minimization analysis |
title_sort | home-based subcutaneous immunoglobulin for chronic inflammatory demyelinating polyneuropathy patients: a swiss cost-minimization analysis |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7688145/ https://www.ncbi.nlm.nih.gov/pubmed/33237959 http://dx.doi.org/10.1371/journal.pone.0242630 |
work_keys_str_mv | AT perraudinclemence homebasedsubcutaneousimmunoglobulinforchronicinflammatorydemyelinatingpolyneuropathypatientsaswisscostminimizationanalysis AT bourdinaline homebasedsubcutaneousimmunoglobulinforchronicinflammatorydemyelinatingpolyneuropathypatientsaswisscostminimizationanalysis AT vicinoalex homebasedsubcutaneousimmunoglobulinforchronicinflammatorydemyelinatingpolyneuropathypatientsaswisscostminimizationanalysis AT kuntzerthierry homebasedsubcutaneousimmunoglobulinforchronicinflammatorydemyelinatingpolyneuropathypatientsaswisscostminimizationanalysis AT bugnonolivier homebasedsubcutaneousimmunoglobulinforchronicinflammatorydemyelinatingpolyneuropathypatientsaswisscostminimizationanalysis AT bergerjerome homebasedsubcutaneousimmunoglobulinforchronicinflammatorydemyelinatingpolyneuropathypatientsaswisscostminimizationanalysis |